Clinical trials: HCC, open to volunteers
Liver Transplantation, HCC
HOPE Against Cancer Recurrence in HCC
Liver transplantation is often performed to treat liver cancer, or hepatocellular carcinoma (HCC), in patients with impaired liver function due to cirrhosis. A shortcoming, however, is tumor recurrence after transplantation.
- Conditions
- Liver Transplantation, HCC, Oncological Outcomes
- Trial name
- HOPE4Cancer (NCT06717919)
- Testing
- Hypothermic oxygenated perfusion, Conventional cold storage
- Where
- 37 sites in United States, Austria and 15 more
- Volunteers
- 220 people
- Sponsor
- Philipp Dutkowski
Hepatocellular Carcinoma (HCC)
Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver Resection
Vessels that encapsulate tumor clusters (VETC) are a novel invasive metastatic factor in hepatocellular carcinoma (HCC), operating independently of the epithelial-mesenchyme transition (EMT).
- Trial name
- NCT07077798
- Testing
- Sintilimab, Lenvatinib
- Volunteers
- 234 people
- Sponsor
- Wan-Guang Zhang
Hepatocellular Carcinoma Non-resectable
mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria
This study was designed to evaluate the effectiveness and safety of mFOLFOX7（Oxaliplatin,Calcium Levofolinate,Fluorouracil） combined with Apatinib and Camrelizumab for Hepatocellular Carcinoma.
- Trial name
- NCT06607107
- Testing
- mFOLFOX7 combined with Camrelizumab and apatinib
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
HCC
A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC
This is an open-label phase II/III clinical trial enrolling patients with advanced HCC who have failed prior ICIs. The phase II portion consists of a part A dose-escalation stage and a part B dose-expansion stage.
- Trial name
- NCT07589244
- Testing
- VRT106, VRT106 in combination with camrelizumab and apatinib, Investigator's Choice of Standard of Care
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Guangzhou Virotech Pharmaceutical Co., Ltd.
Hepatocellular Carcinoma, Liver Cancer
Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Relapsed Hepatocellular Carcinoma
The goal of this clinical trial is to learn how well BGB-B2033 works and how safe it is in people with hepatocellular carcinoma (HCC) who have previously received up to two treatments that included programmed cell death protein 1…
- Trial name
- NCT07836530
- Testing
- BGB-B2033, Lenvatinib, Sorafenib
- Volunteers
- 492 people
- Sponsor
- BeOne Medicines
Advanced Hepatocellular Carcinoma (HCC)
Phase 2 Study of WGI-0301 for Advanced HCC
The purpose of this study is to determine the MTD of WGI-0301 in combination with Sorafenib for advanced Hepatocellular Carcinoma (HCC) and assess its safety and efficacy in adults with advanced unresectable HCC who have…
- Trial name
- NCT06309485
- Testing
- WGI-0301 at MTD/RP2D dose IV infusion, QW, WGI-0301 at MTD/RP2D -1 dose IV infusion, QW, Sorafenib 400 mg PO, BID continuously
- Where
- 9 sites in China, Hong Kong
- Volunteers
- 60 people
- Sponsor
- Zhejiang Haichang Biotech Co., Ltd.
Hepatocellular Carcinoma
Oral Zinc Supplementation Combined With Targeted Immunotherapy for Unresectable or Advanced Hepatocellular Carcinoma
This study will look at whether adding daily oral zinc supplements to targeted therapy plus immunotherapy may help people with unresectable or advanced hepatocellular carcinoma, a common type of liver cancer.
- Trial name
- ZINC-1LT/IOHCC (NCT07793695)
- Testing
- Oral elemental zinc supplementation, 20 mg/day, Oral elemental zinc supplementation, 30 mg/day, Standard-of-care targeted therapy plus immunotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Anhui Provincial Hospital
Carcinoma, Hepatocellular, Hepatitis C, Chronic
Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)
The goal of this study is to evaluate whether the standardized liver cancer risk stratification management can effectively improve the early diagnosis rate of liver cancer in the targeted risk population in China.
- Conditions
- Carcinoma, Hepatocellular, Hepatitis C, Chronic, Hepatitis B, Chronic, Cirrhosis, Liver
- Trial name
- dSEARCH (NCT05870969)
- Testing
- Liver cancer surveillance every 3 months, Liver cancer surveillance every 6 months, Liver cancer surveillance annually
- Where
- China
- Volunteers
- 20,000 people
- Sponsor
- Ruijin Hospital
Hepato Cellular Carcinoma (HCC), Hand Foot Skin Syndrome
SHIELD: Sorafenib Hand-foot Syndrome Inhibition With Pre-Emptive Local Delivery of Topical Indomethacin
SHIELD is a single-center, open-label, single-arm prospective study designed to evaluate whether pre-emptive topical indomethacin can reduce sorafenib-associated hand-foot syndrome (HFS) in patients with advanced hepatocellular…
- Trial name
- NCT07560566
- Testing
- Topical Indomethacin
- Where
- Taiwan
- Volunteers
- 39 people
- Sponsor
- National Taiwan University Hospital
Hepatobiliary Cancer, Pancreatic Cancer
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
This is a prospective pilot protocol investigating whether ctDNA detection be improved by sampling the cancer draining vein versus the standard practice of sampling from a peripheral vein in patients who are undergoing biopsies…
- Conditions
- Hepatobiliary Cancer, Pancreatic Cancer, Hepatocellular Carcinoma, Cholangiocarcinoma
- Trial name
- NCT05497531
- Testing
- ctDNA Blood Collection
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of California, Irvine
Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Carcinoma
Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma
Safety and Efficacy Evaluation of Tremelimumab Plus Durvalumab(MEDI4736) in Combination with Concurrent Transarterial Chemoembolization in Unresectable Hepatocellular carcinoma
- Trial name
- NCT06911255
- Testing
- Tremelimumab Plus Durvalumab (MEDI4736), Transarterial chemoembolization (TACE)
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- Yoon Jun Kim
Advanced Hepatocellular Carcinoma
Lenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma (LEN-TAC Study)
Compared to systemic therapy alone, conversion therapy is promising to improve the prognosis of patients with advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT05738616
- Testing
- Lenvatinib combined with TACE and Camrelizumab
- Where
- China
- Volunteers
- 196 people
- Sponsor
- Wen Tianfu
Hepatocellular Carcinoma Resectable
Drug Sensitivity Testing-Based Tumor Organoids to Guide Adjuvant Therapy After Hepatectomy for Primary Liver Cancer
This is a single-center, prospective, non-randomized, open-label, phase II clinical trial aiming to evaluate the efficacy and feasibility of using patient-derived tumor organoid drug sensitivity testing (ODST) to guide…
- Trial name
- NCT07363356
- Testing
- Organoid Drug Sensitivity Testing-Guided Therapy
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hepato Cellular Carcinoma
Ebastine for Adjuvant Treatment of Tumor Budding-Positive Liver Cancer After Surgery
This study evaluates ebastine, an FAK (focal adhesion kinase) inhibitor, as adjuvant therapy to reduce the risk of recurrence in patients with hepatocellular carcinoma (HCC) who have undergone curative hepatectomy and whose…
- Trial name
- NCT07734766
- Testing
- Ebastine
- Volunteers
- 45 people
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
Postoperative Bile Leak, Focal Liver Lesions
Prevention of Bile Leakage After Liver Resection in Children
Bile leakage is a clinically important complication after liver resection in children and may require prolonged drainage, additional radiological or endoscopic procedures, or repeat surgery.
- Trial name
- NCT07867522
- Testing
- prophylactic extrahepatic biliary drainage during liver resection
- Where
- Russia
- Volunteers
- 12 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
HCC - Hepatocellular Carcinoma, Iparomlimab and Tuvonralimab Injection
A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk
This study aims to investigate the efficacy and safety of neoadjuvant therapy with Iparomlimab and Tuvonralimab Injection (anti-PD-1 and anti-CTLA-4 antibody combination) in patients with resectable hepatocellular carcinoma at…
- Conditions
- HCC - Hepatocellular Carcinoma, Iparomlimab and Tuvonralimab Injection, Neoadjuvant Immunotherapy
- Trial name
- NCT07515469
- Testing
- Iparomlimab and Tuvonralimab
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
High Risk of Recurrence
Innovative Diagnosis and Therapy in LDLT Patients With High-risk Hepatocellular Carcinoma
The challenge of LDLT to HCC is that tumors with a high risk of recurrence have a high rate of recurrence after liver transplantation, and there is no appropriate treatment to prevent HCC recurrence after transplantation in these…
- Trial name
- NCT06327269
- Testing
- Lenvatinib 10 mg
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Chang Gung Memorial Hospital
Hepatocellular Carcinoma
The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma
The ABC-HCC trial is a Phase IIIb, randomised, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab plus bevacizumab versus TACE in patients with intermediate-stage HCC.
- Trial name
- NCT04803994
- Testing
- Atezolizumab, Bevacizumab, TACE
- Where
- 72 sites in Austria, France and 4 more
- Volunteers
- 434 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Hepatocellular Carcinoma
Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the 7th most common cancer worldwide but is the 4th deadliest, because diagnosis tend to be late and current systemic therapies are poorly efficacious.
- Trial name
- EMPHASIS (NCT05516628)
- Testing
- Surgical Resection, Adjuvant Atezolizumab-Bevacizumab Therapy
- Where
- 6 sites in Singapore
- Volunteers
- 30 people
- Sponsor
- National Cancer Centre, Singapore
Primary Liver Cancer
cfDNA Methylation for Liver Cancer Recurrence Detection
Through follow-up testing of patients with primary liver cancer who underwent hepatectomy, liver transplantation, ablation therapy, or transarterial chemoembolization (TACE), a blinded comparative trial was conducted at each…
- Trial name
- NCT07466602
- Testing
- plasma GNB4 and Riplet genes methylation detection
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Wuhan Ammunition Life-tech Co., Ltd